Información del artículo
El Texto completo está disponible en PDF
References
[1.]
J.A. Sterne, M.A. Hernan, B. Ledergerber, K. Tilling, R. Weber, P. Sendi, et al.
Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study.
Lancet, 366 (2005), pp. 378-384
[2.]
G. Greub, B. Ledergerber, M. Battegay, P. Grob, L. Perrin, H. Furrer, et al.
Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study.
Lancet, 356 (2000), pp. 1800-1805
[3.]
A. Mocroft, B. Ledergerber, C. Katlama, O. Kirk, P. Reiss, A. d’Arminio Monforte, et al.
Decline in the AIDS and death rates in the EuroSIDA study: an observational study.
Lancet, 362 (2003), pp. 22-29
[4.]
A. Mocroft, R. Brettle, O. Kirk, A. Blaxhult, J.M. Parkin, F. Antunes, et al.
Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study.
AIDS, 16 (2002), pp. 1663-1671
[5.]
C. Lewden, D. Salmon, P. Morlat, S. Bevilacqua, E. Jougla, F. Bonnet, et al.
Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS.
Int J Epidemiol, 34 (2005), pp. 121-130
[6.]
J.M. Tassie, S. Grabar, R. Lancar, J. Deloumeaux, M. Bentata, D. Costagliola, et al.
Time to AIDS from 1992 to 1999 in HIV-1-infected subjects with known date of infection.
J Acquir Immune Defic Syndr, 30 (2002), pp. 81-87
[7.]
A.I. Van Sighem, M.A. Van de Wiel, A.C. Ghani, M. Jambroes, P. Reiss, I.C. Gyssens, et al.
Mortality and progression to AIDS after starting highly active antiretroviral therapy.
AIDS, 17 (2003), pp. 2227-2236
[8.]
M. Herida, M. Mary-Krause, R. Kaphan, J. Cadranel, I. Poizot-Martin, C. Rabaud, et al.
Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients.
J Clin Oncol, 21 (2003), pp. 3447-3453
[9.]
G.M. Clifford, J. Polesel, M. Rickenbach, L. Dal Maso, O. Leiser, A. Kofler, et al.
Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.
J Natl Cancer Inst, 97 (2005), pp. 425-432
[10.]
M. Mary-Krause, L. Cotte, A. Simon, M. Partisani, D. Costagliola, Clinical Epidemiology Group from the French Hospital Database.
Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men.
AIDS, 17 (2003), pp. 2479-2486
[11.]
N. Friis-Møller, C.A. Sabin, R. Weber, A. d’Arminio Monforte, W.M. El-Sadr, P. Reiss, et al.
Combination antiretroviral therapy and the risk of myocardial infarction.
N Engl J Med, 349 (2003), pp. 1993-2003
[12.]
V. Le Moing, C. Rabaud, V. Journot, X. Duval, L. Cuzin, J.P. Cassuto, et al.
Incidence and risk factors of bacterial pneumonia requiring hospitalization in HIV-infected patients started on a protease inhibitor-containing regimen.
HIV Med, 7 (2006), pp. 261-267
[13.]
R. Murri, A. Ammassari, M.P. Trotta, A. De Luca, S. Melzi, C. Minardi, et al.
Patient-reported and physician-estimated adherence to HAART: social and clinic center-related factors are associated with discordance.
J Gen Intern Med, 19 (2004), pp. 1104-1110
[14.]
M. Preau, C. Leport, D. Salmon-Ceron, P. Carrieri, H. Portier, G. Chene, et al.
Health-related quality of life and patient-provider relationships in HIV-infected patients during the first three years after starting PI-containing antiretroviral treatment.
AIDS Care, 16 (2004), pp. 649-661
[15.]
A. Caro-Murillo, J. Castilla, S. Pérez-Hoyos, J.M. Miró, D. Podzamczer, R.R. Rubio, et al.
Cohorte RIS de pacientes con infección por VIH sin tratamiento antirretroviral previo (CoRIS): metodología y primeros resultados.
Enferm Infecc Microbiol Clin, 25 (2007), pp. 23-31
[16.]
T.E. Yamashita, J.P. Phair, A. Munoz, J.B. Margolick, R. Detels, S.J. O’Brien, et al.
Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study.
AIDS, 15 (2001), pp. 735-746
[17.]
C.A. Sabin, T. Hill, F. Lampe, R. Matthias, S. Bhagani, R. Gilson, et al.
Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study.
BMJ, 330 (2005), pp. 695
[18.]
R. Thiebaut, G. Chene, H. Jacqmin-Gadda, P. Morlat, P. Mercie, M. Dupon, et al.
Time-updated CD4+ T lymphocyte count and HIV RNA as major markers of disease progression in naive HIV-1-infected patients treated with a highly active antiretroviral therapy: the Aquitaine cohort, 1996-2001.
J Acquir Immune Defic Syndr, 33 (2003), pp. 380-386
[19.]
S. Grabar, V. Le Moing, C. Goujard, M. Egger, C. Leport, M.D. Kazatchkine, et al.
Response to highly active antiretroviral therapy at 6 months and long-term disease progression in HIV-1 infection.
J Acquir Immune Defic Syndr, 39 (2005), pp. 284-292
[20.]
CASCADE Collaboration.
Survival after introduction of HAART in people with known duration of HIV-1 infection.
Lancet, 355 (2000), pp. 1158-1159
[21.]
C. Smit, R. Geskus, S. Walker, C. Sabin, R. Coutinho, K. Porter, et al.
Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion.
AIDS, 20 (2006), pp. 741-749
[22.]
N. Friis-Moller, R. Weber, P. Reiss, R. Thiebaut, O. Kirk, A. d’Arminio Monforte, et al.
Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study.
AIDS, 17 (2003), pp. 1179-1193
[23.]
M. Egger, M. May, G. Chêne, A.N. Phillips, B. Ledergerber, F. Dabis, et al.
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.
Lancet, 360 (2002), pp. 119-129
Copyright © 2007. Elsevier España S.L.. All rights reserved
